These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 22269095)

  • 1. Determination of different putative allosteric binding pockets at the lutropin receptor by using diverse drug-like low molecular weight ligands.
    Heitman LH; Kleinau G; Brussee J; Krause G; Ijzerman AP
    Mol Cell Endocrinol; 2012 Apr; 351(2):326-36. PubMed ID: 22269095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substituted terphenyl compounds as the first class of low molecular weight allosteric inhibitors of the luteinizing hormone receptor.
    Heitman LH; Narlawar R; de Vries H; Willemsen MN; Wolfram D; Brussee J; Ijzerman AP
    J Med Chem; 2009 Apr; 52(7):2036-42. PubMed ID: 19296599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [3H]Org 43553, the first low-molecular-weight agonistic and allosteric radioligand for the human luteinizing hormone receptor.
    Heitman LH; Oosterom J; Bonger KM; Timmers CM; Wiegerinck PH; Ijzerman AP
    Mol Pharmacol; 2008 Feb; 73(2):518-24. PubMed ID: 17989351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hybrid ortho/allosteric ligands for the adenosine A(1) receptor.
    Narlawar R; Lane JR; Doddareddy M; Lin J; Brussee J; Ijzerman AP
    J Med Chem; 2010 Apr; 53(8):3028-37. PubMed ID: 20345101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects.
    Valant C; Felder CC; Sexton PM; Christopoulos A
    Mol Pharmacol; 2012 Jan; 81(1):41-52. PubMed ID: 21989256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives.
    Urwyler S
    Pharmacol Rev; 2011 Mar; 63(1):59-126. PubMed ID: 21228259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allosteric enhancers of A1 adenosine receptors increase receptor-G protein coupling and counteract Guanine nucleotide effects on agonist binding.
    Figler H; Olsson RA; Linden J
    Mol Pharmacol; 2003 Dec; 64(6):1557-64. PubMed ID: 14645687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone/chorionic gonadotropin receptor (LHCGR).
    Jäschke H; Neumann S; Moore S; Thomas CJ; Colson AO; Costanzi S; Kleinau G; Jiang JK; Paschke R; Raaka BM; Krause G; Gershengorn MC
    J Biol Chem; 2006 Apr; 281(15):9841-4. PubMed ID: 16488885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A common intracellular allosteric binding site for antagonists of the CXCR2 receptor.
    Salchow K; Bond ME; Evans SC; Press NJ; Charlton SJ; Hunt PA; Bradley ME
    Br J Pharmacol; 2010 Apr; 159(7):1429-39. PubMed ID: 20233217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities.
    De Amici M; Dallanoce C; Holzgrabe U; Tränkle C; Mohr K
    Med Res Rev; 2010 May; 30(3):463-549. PubMed ID: 19557759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors.
    Tränkle C; Weyand O; Voigtländer U; Mynett A; Lazareno S; Birdsall NJ; Mohr K
    Mol Pharmacol; 2003 Jul; 64(1):180-90. PubMed ID: 12815174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor.
    Heitman LH; Ye K; Oosterom J; Ijzerman AP
    Mol Pharmacol; 2008 Jun; 73(6):1808-15. PubMed ID: 18344315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of multiple allosteric sites on the M1 muscarinic acetylcholine receptor.
    Espinoza-Fonseca LM; Trujillo-Ferrara JG
    FEBS Lett; 2005 Dec; 579(30):6726-32. PubMed ID: 16310776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors.
    Chen Y; Goudet C; Pin JP; Conn PJ
    Mol Pharmacol; 2008 Mar; 73(3):909-18. PubMed ID: 18056795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric binding sites on muscarinic acetylcholine receptors.
    Wess J
    Mol Pharmacol; 2005 Dec; 68(6):1506-9. PubMed ID: 16183853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fishing for allosteric sites on GABA(A) receptors.
    Olsen RW; Chang CS; Li G; Hanchar HJ; Wallner M
    Biochem Pharmacol; 2004 Oct; 68(8):1675-84. PubMed ID: 15451411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of a putative steroidal allosteric site on glycoprotein hormone receptors.
    Rossi M; Dimida A; Ferrarini E; Silvano E; De Marco G; Agretti P; Aloisi G; Simoncini T; Di Bari L; Tonacchera M; Giorgi F; Maggio R
    Eur J Pharmacol; 2009 Nov; 623(1-3):155-9. PubMed ID: 19766106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site.
    Jacobson MA; Kreatsoulas C; Pascarella DM; O'Brien JA; Sur C
    Mol Pharmacol; 2010 Oct; 78(4):648-57. PubMed ID: 20660086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor.
    Steinfeld T; Mammen M; Smith JA; Wilson RD; Jasper JR
    Mol Pharmacol; 2007 Aug; 72(2):291-302. PubMed ID: 17478612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation.
    Hoare SR; Fleck BA; Gross RS; Crowe PD; Williams JP; Grigoriadis DE
    Mol Pharmacol; 2008 May; 73(5):1371-80. PubMed ID: 18239030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.